Cordeu Lucía, Cubedo Elena, Bandrés Eva, Rebollo Amaia, Sáenz Xabi, Chozas Hector, Victoria Domínguez Ma, Echeverría Mikel, Mendivil Beatriz, Sanmartin Carmen, Palop Juan Antonio, Font María, García-Foncillas Jesús
Laboratorio de Farmacogenómica, Area de Oncología, Centro de Investigación Médica Aplicada, Pamplona, Spain.
Bioorg Med Chem. 2007 Feb 15;15(4):1659-69. doi: 10.1016/j.bmc.2006.12.010. Epub 2006 Dec 12.
In order to obtain less toxic antitumoral compounds we have looked for novel compounds with anticancer activity based on proapoptotic mechanisms. The compounds studied in this work are derivatives of bicyclic aromatic systems like pyrido[2,3-d]pyrimidines. The potential antitumoral activity of the compounds was evaluated in vitro by examining their cytotoxic effects against human breast, colon, and bladder cancer lines (MD-MBA-231, HT-29, and T-24). The data indicate that HC-6 is a potent anticancer drug showing dose-dependent cytostatic and proapoptotic effects through activation of two different signaling pathways namely a pathway leading to cell cycle arrest and a transcription-independent route leading to rapid apoptosis.
为了获得毒性较小的抗肿瘤化合物,我们基于促凋亡机制寻找具有抗癌活性的新型化合物。本研究中所研究的化合物是双环芳香体系如吡啶并[2,3-d]嘧啶的衍生物。通过检测这些化合物对人乳腺癌、结肠癌和膀胱癌细胞系(MD-MBA-231、HT-29和T-24)的细胞毒性作用,在体外评估了它们潜在的抗肿瘤活性。数据表明,HC-6是一种有效的抗癌药物,通过激活两条不同的信号通路显示出剂量依赖性的细胞生长抑制和促凋亡作用,这两条通路一条导致细胞周期停滞,另一条是不依赖转录的途径导致快速凋亡。